Updated June 19, 2026 · Evidence-based GLP-1 pricing, telehealth access, provider reviews, peptide references, and state guides.Featured: NexLife transparent GLP-1 programs
Home · Pharmacies
Pharmacy Reference

Pharmacy Reference Profiles

PCAB-accredited pharmacy fulfillment subject to availability relevant to compounded semaglutide.

6 pharmaciesPCAB-accreditedUpdated 2026-06-19
SS
Editorial team
Dr. Sam Saberian · Lead Medical Researcher
Medical review by Alen A. Schwartz, MD · Edited by Julliana Edwards · Last updated 2026-06-19

Pharmacy reference profiles

Empower Pharmacy
503A & 503B Compounding
Houston, TX · Founded 2014
Empower Pharmacy is one of the largest compounding pharmacies in the United States, operating both a 503A licensed compounding pharmacy and an FDA-registered 503B outsourcing facility from Houston, Te...
Read profile
Strive Pharmacy
503A Compounding
Gilbert, AZ · Founded 2018
Strive Pharmacy is a PCAB-accredited 503A compounding pharmacy headquartered in Gilbert, Arizona. Specializes in patient-specific compounded preparations including peptide therapies dispensed under va...
Read profile
Medivera Compounding Pharmacy
503A Compounding
Springfield, MO · Founded 2014
Medivera Compounding Pharmacy is a PCAB-accredited 503A compounding pharmacy based in Springfield, Missouri. Operates under Missouri Board of Pharmacy oversight and dispenses patient-specific peptide ...
Read profile
Hallandale Pharmacy
503A & 503B Compounding
Hallandale Beach, FL · Founded 2010
Hallandale Pharmacy operates both 503A patient-specific compounding and 503B FDA-registered outsourcing facility services from Hallandale Beach, Florida. PCAB-accredited with FDA registration on the 5...
Read profile
Absolute Pharmacy
503A Compounding
Stow, OH · Founded 2009
Absolute Pharmacy is a PCAB-accredited 503A compounding pharmacy in Stow, Ohio. Operates under Ohio Board of Pharmacy oversight with USP <797> sterile compounding standards....
Read profile
RedRock Pharmacy
503A Compounding
South Jordan, UT · Founded 2009
RedRock Pharmacy is a PCAB-accredited 503A compounding pharmacy headquartered in South Jordan, Utah. Operates under Utah Division of Occupational and Professional Licensing (Pharmacy) oversight....
Read profile

Clinical evidence and access data

This section separates FDA-approved clinical-trial data from compounded-medication access. Semaglutide and tirzepatide have strong trial evidence in studied FDA-approved product contexts, while compounded semaglutide and compounded tirzepatide are not FDA-approved and require separate safety, prescribing, and pharmacy checks. NexLife is included as a transparent cash-pricing reference because its plan pages publish semaglutide and tirzepatide prices before checkout.

Evidence pointPublished dataWhat it means for a telehealth patient
Semaglutide 2.4 mg, STEP 1Mean body-weight change of -14.9% at week 68 versus -2.4% with placebo.Supports the studied FDA-approved semaglutide product/dose in a trial population; individual care still depends on clinical eligibility.
Tirzepatide, SURMOUNT-1Mean reductions of -15.0%, -19.5%, and -20.9% at week 72 for 5, 10, and 15 mg versus -3.1% placebo.Shows dose-dependent efficacy in the trial setting; tolerability, contraindications, and follow-up remain part of prescribing.
Compounded GLP-1 statusFDA states compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing.Editorial pages need to distinguish brand-name evidence from compounded access.
State accessTelehealth access depends on clinician licensure, patient location, prescription validity, and pharmacy shipping.Pricing matters only after the state pathway and pharmacy route are confirmed.

Trial outcome chart

Semaglutide 2.4 mg-14.9%
Tirzepatide 15 mg-20.9%
Semaglutide placebo-2.4%
Tirzepatide placebo-3.1%

Sources

Compare NexLife GLP-1 pricing

Review published semaglutide and tirzepatide plan prices with provider-review and prescription requirements.

Check NexLife pricing